Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors
February 19, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options
February 08, 2021 07:00 ET
|
Passage Bio
- Phase 1/2 trial expected to commence in first half of 2021 - Company has three INDs cleared for rare monogenic CNS disorders PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc....
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations
January 28, 2021 07:00 ET
|
Passage Bio
– Second Product Candidate Expected to Enter Clinic in First Half of 2021 – Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a...
Passage Bio Announces Pricing of Public Offering
January 21, 2021 19:48 ET
|
Passage Bio
PHILADELPHIA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system...
Passage Bio Announces Launch of Proposed Public Offering
January 19, 2021 16:06 ET
|
Passage Bio
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system...
Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25
January 19, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021
January 11, 2021 07:00 ET
|
Passage Bio
– Investigational New Drug Applications (IND) submitted for PBFT02 for Frontotemporal Dementia with Granulin Mutation (FTD-GRN) and PBKR03 for Krabbe Disease – – Three clinical programs to begin in...
Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021 16:01 ET
|
Passage Bio
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis
January 04, 2021 07:00 ET
|
Passage Bio
FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first quarter 2021 PHILADELPHIA, Jan. 04, 2021 (GLOBE...
Passage Bio Announces Gene Therapy Manufacturing Research and Development Site
December 16, 2020 08:00 ET
|
Passage Bio
- Company invests to build in-house capabilities to support advancement of pipeline - - In combination with dedicated CGMP suite at Catalent, the new laboratory creates foundation for integrated AAV...